Search

everythinglearnresearchcommunity

for

Search:↓

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

Two patients with stubborn hair loss grew hair after PDRN injections.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.

PRP injection for hair growth can cause reversible vision loss due to inflammatory optic neuropathy.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Provenge extends prostate cancer survival by about 4 months.

Nilotinib may cause gray hair to return to its original color.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Apremilast helps regrow hair in hard-to-treat alopecia areata.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.